Intellia Therapeutics: Hereditary Angioedema BLA Completion and ATTR Study Updates

Intellia Therapeutics is on track for a 2H26 BLA completion for its HAE therapy following positive Phase 3 data. Meanwhile, its Phase 3 ATTR trials have resumed screening after clinical hold resolution, with cash runway extending into 2028.

Key Takeaways

• 1.Intellia plans to complete a rolling BLA submission for lonvo-z in hereditary angioedema (HAE) in 2H26, following positive Phase 3 HAELO data.
• 2.Phase 3 ATTR studies (MAGNITUDE and MAGNITUDE-2) are advancing patient screening following the resolution of FDA clinical holds.
• 3.The company maintains a solid cash position of approximately $517.2mn, extended by a recent $207mn offering, providing a runway into 2028.

Table of Contents

• Rolling BLA submission for lonvo-z in HAE will complete in 2H post positive Ph3 results
• Patient screening activities are advancing in both Ph3 ATTR studies post clinical hold resolution
• 1Q26 EPS vs. GSe
• Valuation and Risks
• Disclosure Appendix

Document Preview

Page 1 of 5

Subscribe for full accessStart Free Trial